ACM
SAGE

Asymmetry Capital Management’s Sage Therapeutics SAGE Stock Holding History

Asymmetry Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-229,117
Closed -$10.2M – 37
2021
Q3 		$10.2M Buy
+229,117
New +$10.5M 6.1% 5
2021
Q2 		– Sell
-79,650
Closed -$5.96M – 33
2021
Q1 		$5.96M Sell
79,650
-102,000
-56% -$8.36M 3.08% 16
2020
Q4 		$15.7M Buy
181,650
+79,188
+77% +$5.84M 7.17% 2
2020
Q3 		$6.26M Sell
102,462
-94,787
-48% -$4.8M 4.03% 11
2020
Q2 		$8.2M Buy
+197,249
New +$7.16M 6.28% 4

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Asymmetry Capital Management's SAGE Position: Q4 2021 in Review

Asymmetry Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2021, closing a stake of 229,117 shares — an estimated $10.2M sold.

Asymmetry Capital Management first reported a position in SAGE in Q2 2020 and held it in 5 quarters. The position peaked at $15.7M in Q4 2020. 217 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

  • Asymmetry Capital Management reported no remaining Sage Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 229,117 Sage Therapeutics shares in Q4 2021, an estimated $10.2M.
  • Asymmetry Capital Management first reported a position in Sage Therapeutics in Q2 2020 and held it in 5 quarters.
  • Asymmetry Capital Management's Sage Therapeutics position peaked at $15.7M in Q4 2020.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.